Related Experiment Video
Updated: Aug 10, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Imputation of Baseline LDL Cholesterol Concentration in Patients with Familial Hypercholesterolemia on Statins or
Isabelle Ruel1, Sumayah Aljenedil1, Iman Sadri1
1Research Institute of the McGill University Health Centre, Royal Victoria Hospital, Montreal, QC, Canada.
Insights
A new algorithm accurately estimates baseline LDL cholesterol (LDL-C) for Familial Hypercholesterolemia (FH) patients, even if they are already on statin therapy. This tool aids in diagnosing FH and initiating timely treatment for cardiovascular disease risk.
Area of Science:
- Cardiovascular Genetics
- Lipid Metabolism
- Clinical Diagnostics
Background:
- Familial Hypercholesterolemia (FH) is a common genetic disorder characterized by elevated LDL cholesterol (LDL-C), increasing the risk of premature atherosclerotic cardiovascular disease (ASCVD).
- Accurate diagnosis of FH is crucial for initiating lifelong management, including intensive pharmacological therapy.
- Baseline LDL-C levels are essential for FH diagnosis but often unavailable due to prior statin treatment.
Purpose of the Study:
- To validate a novel algorithm designed to estimate baseline LDL-C concentrations in patients with FH.
- To assess the algorithm's utility in clinical settings where baseline LDL-C measurements are missing.
Main Methods:
- A cohort of 1297 patients was initially examined to validate the imputation algorithm.
- Baseline LDL-C was compared with imputed values obtained within 18 months of statin therapy initiation.
- Data from 951 patients, after exclusions for missing data or non-standard treatments, were analyzed.
Main Results:
- The mean baseline LDL-C was 243.0 mg/dL, while the mean imputed baseline LDL-C was 244.2 mg/dL (P = 0.48), showing no significant difference.
- The algorithm demonstrated accuracy in estimating pre-treatment LDL-C levels.
- No variations in treatment response were observed based on patient sex or the specific statin/ezetimibe used.
Conclusions:
- A validated method for estimating baseline LDL-C in FH patients is now available.
- This tool can assist clinicians in diagnosing FH, particularly when baseline lipid levels are not recorded.
- Improved diagnostic capabilities can lead to earlier intervention and better management of cardiovascular risk in FH patients.
Background:
Familial hypercholesterolemia (FH) is the most frequent genetic disorder seen clinically and is characterized by increased LDL cholesterol (LDL-C) (>95th percentile), family history of increased LDL-C, premature atherosclerotic cardiovascular disease (ASCVD) in the patient or in first-degree relatives, presence of tendinous xanthomas or premature corneal arcus, or presence of a pathogenic mutation in the LDLR, PCSK9, or APOB genes. A diagnosis of FH has important clinical implications with respect to lifelong risk of ASCVD and requirement for intensive pharmacological therapy. The concentration of baseline LDL-C (untreated) is essential for the diagnosis of FH but is often not available because the individual is already on statin therapy.
Methods:
To validate a new algorithm to impute baseline LDL-C, we examined 1297 patients. The baseline LDL-C was compared with the imputed baseline obtained within 18 months of the initiation of therapy. We compared the percent reduction in LDL-C on treatment from baseline with the published percent reductions.
Results:
After eliminating individuals with missing data, nonstandard doses of statins, or medications other than statins or ezetimibe, we provide data on 951 patients. The mean ± SE baseline LDL-C was 243.0 (2.2) mg/dL [6.28 (0.06) mmol/L], and the mean ± SE imputed baseline LDL-C was 244.2 (2.6) mg/dL [6.31 (0.07) mmol/L] (P = 0.48). There was no difference in response according to the patient's sex or in percent reduction between observed and expected for individual doses or types of statin or ezetimibe.
Conclusions:
We provide a validated estimation of baseline LDL-C for patients with FH that may help clinicians in making a diagnosis.
More Related Videos
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Lipids: Dietary Sources and Requirements
Cholesterol: Significance and Regulation
Considering cholesterol and...
Pharmacogenomics: Identification of New Drug Targets
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...

